NEW YORK (GenomeWeb News) – Qiagen today announced two exclusive licensing deals aimed at developing companion diagnostic tests for glioblastoma, lymphoma, and other cancers.

In one deal, Qiagen has licensed an option on FGFR-TACC fusion genes from Columbia University. Qiagen plans to develop a diagnostic test based on the biomarker for doctors to use in identifying patients who may benefit from targeted treatments currently under development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.